Background: Different regulators or effectors of the metastatic cascade can be of prognostic and/or predictive significance. Cathepsin-D and nm23 operate at different levels of the metastatic process and have not yet been analyzed in combination in ovarian cancer.
Introduction
About two-thirds of the patients with ovarian cancer have FIGO stage III or IV disease at diagnosis, a situation where tumor cells have metastasized to the upper abdomen or the parenchyma of organs such as liver, spleen, pleura or lungs. In spite of the standard use of debulking surgery and combination chemotherapy, long term survival and cure rates are still low, making ovarian cancer the most lethal of the gynecological malignancies [1] . Tumor metastasis, a major cause of death in cancer patients, is a cascade of interrelated, sequential steps that must be completed by tumor cells, and in which failure at any of the steps aborts the whole process [2] . Elements of this metastatic cascade may be used as factors predicting prognosis or response to chemotherapy, and some of them, such as angiogenesis and colonization of tumor cells at the metastatic site, are promising therapeutic targets [3] .
Cathepsin-D is a lysosomal acidic protease, present in all cells. Its proteolytic action is thought to participate in the destruction of the extracellular matrix, promoting the spread of cancer cells [4] , and it has also been shown to have an autocrine mitogenic effect in breast cancer cells [5] . Overexpression of human cathepsin-D in rat embryo cells was shown to correlate with increased metastatic ability of these cells in athymic nude mice [6] . Cathepsin-D may be expressed in both epithelial and stromal cells in a single tumor, but the relative importance of either type of expression is unclear in most tumor types studied [7] . Cathepsin-D expression has been investigated in different diseases [8, 9] , but most research has focused on breast cancer, where an association was found between high cathepsin-D levels and poor disease-free survival, especially in node negative patients [10] . In a previous study from our institution, tumor cell cathepsin-D was shown to have independent prognostic value in early stage cervical squamous cell carcinoma [11] . Data on its role in ovarian cancer are scarce [12] [13] [14] , with only a single study examining its prognostic significance [12] .
The nm23 gene was initially cloned as a metastasis suppressor gene, with reduced nm23 mRNA levels correlating with higher metastatic potential in vitro [15] .
To date three human nm23 genes (nm23-Hl, nm23-H2 and DR-nm23) have been identified, coding for distinct but highly conserved and homologous polypeptides [16] . Transfection of human nm23-Hl cDNA into human MDA-MB-435 breast cancer cell lines resulted in a significant reduction of the metastatic potential in vivo [17] . Its significance in human tumors was examined in breast, gastric and hepatocellular cancers and melanoma, where nm23 levels correlated inversely with metastatic potential and/or survival [18] . In contrast, nm23 expression was found to correlate with more aggressive disease in pancreatic cancer and neuroblastoma [16] . Kristensen et al. did not find nm23 expression to be of independent prognostic significance in cervical carcinoma [18] . Studies on ovarian cancer are few [20] [21] [22] [23] [24] [25] [26] , and have generally included so few patients that a multivariate analysis of survival could be performed in only one [20] . We examined the possible prognostic and predictive significance of cathepsin-D and nm23, two factors operative at different levels of the metastatic cascade, in a large cohort of uniformly treated and followed patients with advanced ovarian cancer.
Patients and methods

Patients and samples
Tumor tissue was obtained at first surgery in 185 previously untreated patients with FIGO [27] stage III epithelial ovarian cancer. This patient cohort consisted of all patients consecutively included at the Department of Gynecologic Oncology at the Norwegian Radium Hospital in a multicenter trial on consolidation treatment after second look laparotomy in stage III ovarian cancer patients. Selection criteria were patient age <71 years, Karnofsky index of at least 60, histologically verified and previously untreated stage III epithelial ovarian cancer and s-creatinin < 115 umol/1. All patients were treated between January 1988 and May 1993. Median age was 54 years (range 21-70). Histological slides were reviewed by one pathologist (JMN) without knowledge of the clinical data. Histological classification was performed with the criteria defined by the WHO [28] . Postoperatively, a standard regimen containing cisplatin (50 mg/m 2 q 4 weeks) and epirubicin (50 mg/m q 4 weeks) was used. Second-look laparotomy was performed in 149 of 185 patients. In 35 cases no second-look laparotomy was performed because of clinically evident disease progression, and 1 patient preferred not to undergo the procedure. To assess response, reports from first surgery and second-look laparotomy were reviewed and all tumor measurements were compared. Complete pathological response (CPR) was defined as the disappearance of all tumor at second look laparotomy, with all biopsies and peritoneal washings negative for tumor cells. Microscopical residual disease was defined as the disappearance of all macroscopical tumor lesions, but with the presence of tumor cells in one or more biopsies or peritoneal washings. Partial response (PR) was defined as a 50% or more decrease in size of all bidimensionally measured tumor lesions. Stable disease (SD) was either a decrease in size of less than 50% or an increase in size of less than 25% of one or more measured tumor lesions. Progressive disease (PD) was defined as either a 25% or more increase in the size of one or more clinically measured lesions or the appearance of new disease manifestations or a 25% increase in one or more tumor measurements at second look laparotomy. Response was not evaluable in 10 cases, in 9 because the patient had no macroscopic residual tumor after first surgery and in 1 because of patient refusal to undergo the second-look procedure. All patients were followed up until death or until January 1999. Follow-up information was collected from Abbreviations: CPR -complete pathological response, micro onlymicroscopic residual disease only.
the medical records, and no patients were lost for follow-up. Median follow-up time for patients still alive was 81 months (range 69-125).
A detailed description of patient characteristics is given in Table 1 Immunohistochemistry Sections from formalin-fixed, paraffin-embedded blocks were immunostained using the biotin-streptavidin-peroxidase method (Supersensitive Immunodetection System, LP000-UL, Biogenex, CA, USA) and OptiMax Plus Automated Cell Staining System (Biogenex). Deparaffinized sections were treated with 1% hydrogen peroxide ( ing for nm23 in epithelial tumor cells (x 580).
ical analysis was performed at the Department of Pathology, independently from the clinical data.
Statistical analysis
Differences in proportions were evaluated by the chi-square or Fisher's exact test, whichever was appropriate. Disease-free and corrected survival rates were calculated using the method of Kaplan-Meier [29] . The log-rank test was used for univariate analysis and a Cox proportional hazards regression model was used for multivariate evaluation of survival rates [30] , In multivariate analysis, a backward stepwise selection procedure was used. The hazard proportionality was verified by computing the log minus log against time. The Statistical Package for Social Science (SPSS) was used for the statistical analysis. Statistical significance was considered as P < 0.05.
Results
Immunohistochemistry
One hundred seven of the one hundred eighty-five cases (58%) showed positive cytoplasmic staining for cathepsin-D in the epithelial tumor cells (44 cases (24%) moderate and 63 (34%) strong intensity) (Figure 1 ), whereas stromal cells stained positively in 37 cases (20%). In 25 cases (13.5%), both tumor and stromal cells showed positive staining. Immunohistochemical staining for nm23 was observed in the cytoplasm of tumor cells in 134 of 185 cases (72%) (Figure 2 ). Of these positive cases, 77 (41%) showed moderate and 57 (31%) strong staining intensity. No staining was observed in the cytoplasm of stromal cells.
Clinicopathological correlations
The frequency of immunohistochemical staining in relation to clinical and histopathological parameters is shown in Table 2 . For cathepsin-D, frequencies and correlations are given for epithelial tumor cell staining. Stromal cell staining did not correlate with any of the clinicopathological parameters, and no correlation was found between epithelial and stromal cell cathepsin-D staining either (P -0.212).
Cathepsin-D staining correlated positively with better differentiation (grade 1 versus 2 and 3) of the tumor tissue (P -0.034). Nm23 staining correlated positively with lower age (P = 0.036) and was observed slightly more often in well differentiated (P -0.063) and serous tumors (P -0.057).
None of the factors examined correlated with tumor response after four courses of chemotherapy. However, when examined for each case (not at the cellular level), a high degree of correlation was found between cathepsin-D and nm23 positivity (P = 0.005).
Analysis of survival
At assessment on 1 January 1999, 19 patients (10%) were alive without evidence of disease, 10 (5.5%) were alive with disease, whereas 156 (84.5%) had died of ovarian cancer). The disease-related five-year survival rate for the whole group was 25.4%. The median progression-free survival time was 13 months and the median corrected survival time was 24 months. In univariate analysis age below or above the median (P -0.0192), FIGO substage {P < 0.0001), histological type (P -0.0066), differentiation grade (/> < 0.0001), presence of ascites (P = 0.0003), residual disease (P < 0.0001) and epithelial cell cathepsin-D expression (P -0.0113) ( Figure 3) were associated with corrected survival. Neither stromal cell cathepsin-D expression (P -0.9215), nor nm23 expression (P = 0.8162) correlated with survival. To investigate whether taking into account stromal cathepsin-D ex- pression could increase the prognostic information obtained from epithelial cathepsin-D, a new variable was constructed, considering the different possible combinations of cathepsin-D expression. Twenty-five cases (13.5%) had both stromal and epithelial cell staining, ninety-four (50.5%) had either stromal or epithelial cell staining and sixty-six (36%) had neither. When a new log-rank analysis was performed, two prognostic groups could clearly be identified. Cases with at least one of either epithelial cell or stromal cell cathepsin-D expression had a significantly better corrected survival than The results of the multivariate survival analysis, incorporating the variables that reached significance in the univariate analysis and using corrected survival as endpoint, are shown in Table 3 . Performing the multivariate analysis with either epithelial cell cathepsin-D expression or the combination of epithelial and stromal cell expression, it became clear that cathepsin-D expression only was of independent prognostic significance if both were considered together. In the final model, only degree of differentiation, residual tumor status and combined epithelial and stromal cell cathepsin-D expression retained independent prognostic significance. When progression-free survival was used as end point, only residual disease and degree of differentiation were of independent significance (data not shown).
Discussion
Information on the possible significance of the metastasis-related factors cathepsin-D and nm23 in ovarian cancer is scarce, with only the studies by Ferrandina and Scambia directly examining their prognostic value [12, 20] . We present the largest study on cathepsin-D and nm23 in ovarian cancer to date, focusing on a large cohort of patients with FIGO stage III ovarian cancer, a challenging clinical situation where the tumor already has spread intra-abdominally and/or retroperitoneally. A significant correlation was found between positive nm23 and cathepsin-D expression, a relation that does not seem to be explored in any previous study. It would be interesting to see if this finding can be confirmed at the cellular level and to explore whether there exists a biological link explaining it.
Cathepsin-D seems to be of essential importance in the interactions between epithelial cells and components of the extracellular matrix [31, 32] , and, although most clinical studies do not allow for such a distinction, the cellular source of cathepsin-D has been given increasing importance [33] . In one study on breast cancer patients, positive staining of stromal but not of epithelial tumor cells was associated with poor prognosis [34] . It has been hypothesized that the immunohistochemically detected cathepsin-D in stromal cells could represent cathepsin-D initially secreted by tumor cells, and therefor also is to be considered as a marker for tumor cell related cathepsin-D [33] . Protease secretion from tumor cells could also interfere with important phenomena such as antigen recognition and local immune regulation [35] . In contrast to some [36, 37] , but not all [12] , other studies we found no direct correlation between stromal and epithelial tumor cell cathepsin-D expression. Epithelial cell cathepsin-D alone was not retained in the multivariate Cox model, but when both epithelial and stromal cell expression were considered together, cathepsin-D status became of independent prognostic significance. In contrast to Ferrandina et al. [12] , who could not demonstrate any influence of cathepsin-D on prognosis, we found its expression to be a favourable prognostic feature. However, we feel that the results from that study and ours are difficult to compare. Firstly, Ferrandina et al. have included patients with different stages of the disease, where metastasis-related factors are likely to have a different biological significance. Secondly, of the 133 patients with either stage III or IV disease, they only examined 68 with the same technique that we used, reducing significantly the number of patients that are actually comparable. Also, a different cut-off level for cathepsin-D positivity (25% vs. 10% in our study) was used, leading to a low proportion of epithelial cell positive cases (only 27%). Lastly, it was not stated if all their patients were treated with the same chemotherapy regimen or which regimens were used, a factor that could influence the significance of a potential prognostic or predictive factor. Considering our results, it would seem to be counterintuitive that a factor acting as a mitogen and possibly related to the digestion of extracellular matrix could be of favourable prognostic significance. However, several arguments have to be considered in this regard. First of all, to be effective as a protease, the inactive procathepsin-D has to be autoactivated at an acidic pH [38] . Such acidic conditions are unlikely to be present at the well-perfused invading edge of the tumor. Therefor, other mechanisms, such as digestion of extracellular matrix through ingestion and destruction within large acidic vesicles, have to be postulated. This mechanism has been demonstrated in vitro in breast cancer cells, but not in vivo [39] . Johnson et al. found no correlation between tumor cell cathepsin-D secretion and invasiveness in a series of in vitro experiments with different human breast cancer cell lines [40] . Another fundamental biological argument is found in the recently demonstrated link between cathepsin-D and apoptosis. First, Deiss et al. found that inactivation of cathepsin-D by pepstatin A protected cells from cytokine-induced cell death in a fashion similar to the protection conferred by antisense RNA-expression [41] . Also, expression and processing of cathepsin-D were upregulated during the apoptotic process, and cathepsin-D was suggested to be a positive mediator of apoptosis. In a series of elegant experiments Wu et al. directly linked cathepsin-D to/?55-dependent tumor suppression [42] . They found that cathepsin-D mRNA levels increased in wildtype p53, but not in mutant p53 expressing cell lines, after exposure to adriamycin. Overexpression of cathepsin-D inhibited growth of colon, liver and ovarian cancer cells, and cells completely lacking expression of cathepsin-D exhibited increased resistance to killing by cytotoxic agents. They also provided evidence for a direct interaction between the p53 protein and potential regulatory DNA sequences located upstream of the human cathepsin-D gene. Also, in several clinical studies in breast cancer, cathepsin-D expression was found to be a marker of good prognosis [43, 44] . It seems likely that the nature and significance of protease expression is tissuespecific, or more importantly, that the factors controlling and regulating it, are altered in a different fashion during tumorigenesis in the various types of cancers.
The percentage of nm23 positive cases found in the present material is similar to that in other studies in ovarian cancer [20, 22] . Both nm23 mRNA and protein expression studies have indicated a significant correlation between low nm23 expression and tumor aggressiveness in some tumor types [45] . As far as ovarian cancer is concerned, some investigators have found a correlation between lower nm23 expression and increased frequency of lymph node metastasis [20, 22, 24] . Results from different studies are conflicting, with some authors finding high levels of nm23 expression to be associated with increased metastatic spread of epithelial ovarian cancer [21, 25] . The molecular mechanisms by which nm23 regulates metastatic potential are still undetermined, but nm23 has been linked both to the signal transduction process and to apoptosis [46] [47] [48] . The cohort of patients studied and the design of our study did not allow us to investigate the role of nm23 in ovarian carcinogenesis and progression. We observed a tendency towards correlation between nm23 immunoreactivity and lower age, serous histology and better differentiation, known favourable prognostic features. When nm23 was considered per se, it was not found to be of prognostic value, with survival curves almost overlapping completely. Srivatsa et al. found an association between high nm23 expression and decreased progression-free survival in a small study on 24 patients [23] . The only other study where a multivariate analysis of survival was performed, showed an independent and favourable prognostic significance for positive nm23 expression [20] . Some interesting in vitro experiments on ovarian cancer cell lines showed a positive correlation between nm23 overexpression and increased sensitivity to cisplatin [48] . We could not confirm such a correlation between nm23 expression and response to cisplatin and epirubicin chemotherapy in our patient cohort. One explanation for the differing results might be that the different antibodies used recognize different epitopes. The polyclonal antibody used in the present work was raised against nm23-Hl, but cross-reaction with the nm23-H2 protein, with which it has an 88% sequence homology [16] , is likely.
It may be hypothesized that the metastatic process, parallel to the apoptotic process, depends on the balance between promoting and inhibiting factors rather than on any single one of them. The nature of this balance is likely to be tissue-specific and dependent on other variables such as type of treatment used (if any) and related to the stage of the disease. The cohort studied in the present work consisted entirely of patients with advanced stage disease, where metastasis already had developed. It would be of interest to focus further clinical research on the role of nm23 in ovarian cancer on early stage disease, preferably in a large cohort of stage I patients.
In conclusion, we found cathepsin-D expression (epithelial and stromal cell expression considered together), but not nm23 expression to be of independent prognostic significance in this large cohort of uniformly treated stage III ovarian cancer patients.
